Abstract

POLRMT (RNA polymerase mitochondrial) is responsible for the transcription of mitochondrial genome encoding key components of oxidative phosphorylation. This process is important for cancer cell growth. The current study tested expression and potential functions of POLRMT in non-small cell lung cancer (NSCLC). TCGA cohorts and the results from the local lung cancer tissues showed that POLRMT is overexpressed in human lung cancer tissues. In both primary human NSCLC cells and A549 cells, POLRMT silencing (by targeted lentiviral shRNAs) or knockout (through CRSIPR/Cas9 gene editing method) potently inhibited cell viability, proliferation, migration, and invasion, and induced apoptosis activation. On the contrast, ectopic overexpression of POLRMT using a lentiviral construct accelerated cell proliferation and migration in NSCLC cells. The mtDNA contents, mRNA levels of mitochondrial transcripts, and subunits of respiratory chain complexes, as well as S6 phosphorylation, were decreased in POLRMT-silenced or -knockout NSCLC cells, but increased after ectopic POLRMT overexpression. In vivo, intratumoral injection of POLRMT shRNA adeno-associated virus (AAV) potently inhibited NSCLC xenograft growth in severe combined immune deficiency mice. The mtDNA contents, mRNA levels of mitochondria respiratory chain complex subunits, and S6 phosphorylation were decreased in POLRMT shRNA AAV-injected NSCLC xenograft tissues. These results show that POLRMT is a novel and important oncogene required for NSCLC cell growth in vitro and in vivo.

Highlights

  • Lung cancer is one common malignancy around the world [1, 2]

  • POLRMT overexpression in human lung cancer tissues and cells We first searched the Genotype-Tissue Expression (GTEx) mRNA expression database and BioGPS microarray expression database

  • DNA breaks non-small cell lung cancer (NSCLC) cells with applied genetic modifications were seeded in 96-well plates at a density of 3.5 × 103 cells per well

Read more

Summary

Introduction

Lung cancer is one common malignancy around the world [1, 2]. In 2019 over 228,000 new cases of lung cancer and 142,000 mortality cases were reported in the United States alone. It is the leading cause of cancer-associated mortality [1, 2]. Lung cancer is roughly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [3, 4]. NSCLC accounts over 85% of all cases [3, 4]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call